Keyword: Herceptin

With two oncology blockbuster already facing U.S. biosims, Roche is facing a tough road ahead. Now, a third Roche cancer med is in the firing line.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact."

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.

Two of Roche’s oncology blockbusters are facing dire straits with biosims on the march. Now, a major insurer and PBM is betting on the new guys.

New king Humira, fast-growing Revlimid, Roche's under-attack cancer cash cows. Here are the biopharma's most successful drugs by lifetime sales till 2024.

Roche is appealing a U.S. federal court decision, aiming to shove Amgen's copycats to Avastin and Herceptin off the U.S. market.

For years, Roche’s blockbuster oncology troika dominated sales stateside and abroad. For Herceptin and Avastin, those landmark years could be over.

Reversing an earlier decision, England's drug-price watchdog approved Roche's superstar Ocrevus to treat primary progressive MS.

With a new FDA nod in postsurgery patients—and Herceptin biosimilars looming—Roche's Kadcyla has more space to run.